Squarepoint Ops LLC Lowers Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Squarepoint Ops LLC trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,280 shares of the company's stock after selling 232,496 shares during the quarter. Squarepoint Ops LLC's holdings in Intellia Therapeutics were worth $297,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. raised its position in Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company's stock valued at $33,000 after purchasing an additional 1,398 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock valued at $39,000 after buying an additional 1,550 shares during the period. First Horizon Advisors Inc. lifted its position in Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company's stock worth $58,000 after buying an additional 472 shares during the last quarter. GAMMA Investing LLC boosted its stake in Intellia Therapeutics by 1,322.0% during the second quarter. GAMMA Investing LLC now owns 2,645 shares of the company's stock worth $59,000 after buying an additional 2,459 shares during the period. Finally, EntryPoint Capital LLC boosted its stake in Intellia Therapeutics by 61.1% during the first quarter. EntryPoint Capital LLC now owns 4,122 shares of the company's stock worth $113,000 after buying an additional 1,563 shares during the period. Institutional investors own 88.77% of the company's stock.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the firm's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares of the company's stock, valued at approximately $893,698.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.00% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Stock Up 4.4 %

Shares of NASDAQ NTLA traded up $0.79 during trading hours on Friday, hitting $18.58. 1,485,691 shares of the stock were exchanged, compared to its average volume of 1,526,527. Intellia Therapeutics, Inc. has a 12 month low of $17.09 and a 12 month high of $34.87. The firm has a fifty day moving average price of $21.23 and a 200-day moving average price of $23.21. The company has a market cap of $1.79 billion, a PE ratio of -3.47 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. The company's quarterly revenue was down 48.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.40) earnings per share. As a group, equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on NTLA shares. Evercore ISI upgraded shares of Intellia Therapeutics to a "strong-buy" rating in a report on Friday, August 9th. Truist Financial reaffirmed a "buy" rating and set a $120.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 24th. Canaccord Genuity Group reissued a "buy" rating and issued a $73.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, June 27th. JPMorgan Chase & Co. reduced their price objective on Intellia Therapeutics from $61.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, August 12th. Finally, StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.77.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.